ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Anti-NaPi2b/Exatecan Antibody-drug Conjugate TUB-040

Also written as “TUB-040”, “TUB-040 + Carbo + BEV” and “TUB-040 - Dose escalation”.

Its studies are mostly in Ovarian Neoplasms · Carcinoma, Non-Small-Cell Lung · Endometrial Neoplasms, led by 2 companies.

Drug pageAnti-NaPi2b/Exatecan Antibody-drug Conjugate TUB-040: every studyAll 4 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 2, since Jul 9, 20264 company-led studies, 4 open or runningNext primary completion: Dec 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Tubulisits history only33 open or runningphase 2since Jul 9, 2026Jul 9, 2026Mar 2028phase 2 · NCT07736937
Gilead Sciencesits history only11 open or runningphase 2since Feb 6, 2024Feb 6, 2024Dec 2027phase 2 · NCT06303505

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of every company. Pick one to see its own:

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Feb 6, 2024First study: phase 2 study in Ovarian NeoplasmsNew to Gilead SciencesGilead Sciences · NCT06303505 · 334 planned · United States, Belgium, Germany and more
  2. Jul 9, 2026Tubulis’s first studies: 2 phase 2 studiesNew to TubulisTubulis · NCT07736937, NCT07743541
  3. Sep 1, 2026Phase 2 study in Carcinoma, Non-Small-Cell LungTubulis · NCT07806773 · 80 planned · United States

Ahead

  1. Dec 2027Primary completion: phase 2 study in Ovarian NeoplasmsGilead Sciences · NCT06303505
  2. Mar 2028Primary completion: phase 2 study in Ovarian NeoplasmsTubulis · NCT07736937
  3. May 2029Primary completion: phase 2 study in Carcinoma, Non-Small-Cell LungTubulis · NCT07806773
  4. Sep 2029Primary completion: phase 2 study in Endometrial NeoplasmsTubulis · NCT07743541

TargetBeta

SLC34A2 →read by rule
“An antibody-drug conjugate (ADC) composed of a Fc-silenced, humanized immunoglobulin G1 (IgG1) monoclonal antibody directed against human sodium-dependent phosphate transport protein 2B (SLC34A2; NaPi2b), ”NCIt, by rule

Other programs on SLC34A2

ProgramCompanyFurthest phaseStudies
LM-2417Sino Biopharmaceuticalphase 21

Studies

All 4 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07806773Carcinoma, Non-Small-Cell Lung · United States2Not yet recruitingTubulisMay 202980
NCT07743541Endometrial Neoplasms · United States2Not yet recruitingTubulisSep 2029100
NCT07736937Ovarian Neoplasms · United States, Belgium, Ukraine2RecruitingTubulisMar 202872
NCT06303505Ovarian Neoplasms · United States, Belgium, Germany and more2RecruitingGilead SciencesDec 2027334

How it is read

Names in the registry

  • “TUB-040”, 2 entries
  • “TUB-040 + Carbo + BEV”, 1 entry
  • “TUB-040 - Dose escalation”, 1 entry
  • “TUB-040 - RP2D”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.